Q1: 2026-04-29 Earnings Summary
EPS of -$1.69 beats by $0.10
|
Revenue of
$20.75M
(137.75% Y/Y)
beats by $7.41M
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call April 29, 2026 8:00 AM EDT
Company Participants
Morgan Sanford - Vice President of Investor Relations
Brian Goff - CEO & Director
Cecilia Jones - Chief Financial Officer
Tsveta Milanova - Chief Commercial Officer
Sarah Gheuens - Chief Medical Officer and Head of Research & Development
Conference Call Participants
Samantha Lynn Semenkow - Citigroup Inc. Exchange Research
Alec Stranahan - BofA Securities, Research Division
Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division
Eric Schmidt - Cantor Fitzgerald & Co., Research Division
Marc Frahm - TD Cowen, Research Division
Lydia Erdman - Goldman Sachs Group, Inc., Research Division
Tessa Romero - JPMorgan Chase & Co, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the First Quarter 2026 Agios Financial Results and Business Highlights. [Operator Instructions] Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Morgan Sanford, Head of Investor Relations at Agios. Please go ahead.
Morgan Sanford
Vice President of Investor Relations
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals First Quarter 2026 Financial Results and Business Highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Please note, we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
On the call with me today from Agios are Brian Goff, Chief Executive Officer; Cecilia Jones, Chief Financial Officer; Tsveta Milanova, Chief Commercial Officer; and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development. Following prepared remarks, we
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。